These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32233444)

  • 1. A Self-Adjuvanted, Modular, Antigenic VLP for Rapid Response to Influenza Virus Variability.
    Sharma J; Shepardson K; Johns LL; Wellham J; Avera J; Schwarz B; Rynda-Apple A; Douglas T
    ACS Appl Mater Interfaces; 2020 Apr; 12(16):18211-18224. PubMed ID: 32233444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of H1N1 influenza virus-like particles produced in Nicotiana benthamiana.
    Shoji Y; Prokhnevsky A; Leffet B; Vetter N; Tottey S; Satinover S; Musiychuk K; Shamloul M; Norikane J; Jones RM; Chichester JA; Green BJ; Streatfield SJ; Yusibov V
    Hum Vaccin Immunother; 2015; 11(1):118-23. PubMed ID: 25483524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology.
    Heinimäki S; Lampinen V; Tamminen K; Hankaniemi MM; Malm M; Hytönen VP; Blazevic V
    Virology; 2022 Jan; 566():89-97. PubMed ID: 34894525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective efficacy of baculovirus-derived influenza virus-like particles bearing H5 HA alone or in combination with M1 in chickens.
    Choi JG; Kim MC; Kang HM; Kim KI; Lee KJ; Park CK; Kwon JH; Kim JH; Lee YJ
    Vet Microbiol; 2013 Mar; 162(2-4):623-630. PubMed ID: 23265240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.
    Carter DM; Darby CA; Lefoley BC; Crevar CJ; Alefantis T; Oomen R; Anderson SF; Strugnell T; Cortés-Garcia G; Vogel TU; Parrington M; Kleanthous H; Ross TM
    J Virol; 2016 May; 90(9):4720-4734. PubMed ID: 26912624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.
    Kim MC; Lee YN; Kim YJ; Choi HJ; Kim KH; Lee YJ; Kang SM
    Antiviral Res; 2017 Dec; 148():43-52. PubMed ID: 29107058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response.
    Hodgins B; Yam KK; Winter K; Pillet S; Landry N; Ward BJ
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.
    Venereo-Sanchez A; Gilbert R; Simoneau M; Caron A; Chahal P; Chen W; Ansorge S; Li X; Henry O; Kamen A
    Vaccine; 2016 Jun; 34(29):3371-80. PubMed ID: 27155499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-Linked Glycans and K147 Residue on Hemagglutinin Synergize To Elicit Broadly Reactive H1N1 Influenza Virus Antibodies.
    Huang Y; Owino SO; Crevar CJ; Carter DM; Ross TM
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
    Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
    Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles.
    Ramirez A; Morris S; Maucourant S; D'Ascanio I; Crescente V; Lu IN; Farinelle S; Muller CP; Whelan M; Rosenberg W
    Vaccine; 2018 Feb; 36(6):873-880. PubMed ID: 29306508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.
    Corbett KS; Moin SM; Yassine HM; Cagigi A; Kanekiyo M; Boyoglu-Barnum S; Myers SI; Tsybovsky Y; Wheatley AK; Schramm CA; Gillespie RA; Shi W; Wang L; Zhang Y; Andrews SF; Joyce MG; Crank MC; Douek DC; McDermott AB; Mascola JR; Graham BS; Boyington JC
    mBio; 2019 Feb; 10(1):. PubMed ID: 30808695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
    Quan FS; Huang C; Compans RW; Kang SM
    J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inclusion of membrane-anchored LTB or flagellin protein in H5N1 virus-like particles enhances protective responses following intramuscular and oral immunization of mice.
    Ren Z; Zhao Y; Liu J; Ji X; Meng L; Wang T; Sun W; Zhang K; Sang X; Yu Z; Li Y; Feng N; Wang H; Yang S; Yang Z; Wang Z; Gao Y; Xia X
    Vaccine; 2018 Sep; 36(40):5990-5998. PubMed ID: 30172635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro.
    Hendin HE; Pillet S; Lara AN; Wu CY; Charland N; Landry N; Ward BJ
    Vaccine; 2017 May; 35(19):2592-2599. PubMed ID: 28389100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine.
    Yao Q; Zhang R; Guo L; Li M; Chen C
    J Immunol; 2004 Aug; 173(3):1951-8. PubMed ID: 15265929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.